HC Wainwright Issues Pessimistic Estimate for NRXP Earnings

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Investment analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for NRx Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 3rd. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $0.56 for the year, down from their prior estimate of $0.71. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ FY2030 earnings at $0.99 EPS.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The business had revenue of $1.10 million during the quarter, compared to analysts’ expectations of $1.33 million.

A number of other analysts have also recently issued reports on NRXP. Wolfe Research initiated coverage on NRx Pharmaceuticals in a report on Thursday, October 15th. They set an “outperform” rating for the company. Wall Street Zen downgraded shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Zacks Research lowered shares of NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Wednesday, August 26th. BTIG Research reaffirmed a “buy” rating and set a $10.00 price target on shares of NRx Pharmaceuticals in a research report on Monday, September 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Tuesday. Six equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $34.50.

NRx Pharmaceuticals Price Performance

NRx Pharmaceuticals stock opened at $2.24 on Wednesday. The stock’s 50-day moving average is $3.01 and its 200-day moving average is $2.96. The company has a market cap of $96.99 million, a price-to-earnings ratio of -4.07 and a beta of 2.11. NRx Pharmaceuticals has a 12 month low of $1.62 and a 12 month high of $5.05.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC lifted its stake in shares of NRx Pharmaceuticals by 30.0% during the third quarter. Commonwealth Equity Services LLC now owns 590,768 shares of the company’s stock worth $1,725,000 after purchasing an additional 136,350 shares in the last quarter. SBI Securities Co. Ltd. boosted its position in shares of NRx Pharmaceuticals by 292.1% in the third quarter. SBI Securities Co. Ltd. now owns 20,001 shares of the company’s stock worth $58,000 after buying an additional 14,900 shares during the period. Prime Capital Investment Advisors LLC purchased a new stake in shares of NRx Pharmaceuticals in the third quarter worth about $364,000. Squarepoint Ops LLC purchased a new stake in shares of NRx Pharmaceuticals in the second quarter worth about $54,000. Finally, Ethos Financial Group LLC grew its stake in shares of NRx Pharmaceuticals by 33.6% in the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock valued at $34,000 after buying an additional 4,000 shares in the last quarter. 4.27% of the stock is owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly severe depression and suicidal ideation. The company’s research programs are designed to address conditions in which existing therapies may have limited effectiveness or delayed onset.

NRx’s lead investigational product is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for bipolar depression with acute suicidal ideation.